2011 Startup Companies
TomegaVax will develop novel prophylactic and therapeutic vaccines for unmet medical needs in infectious disease and cancer. TomegVax's core technology is the spread deficient
Cytomegalovirus (CMV) vaccine vector. It was initially developed to address human immunodeficiency virus (HIV). Currently, more than 33 million people are living with HIV/AIDS worldwide with approximately 1.8 million deaths in 2009 alone, including 260,000 children. The core technology can be leveraged to develop vaccines for other forms of infectious disease, such as malaria and tuberculosis, as well as to develop novel anti-cancer vaccines.
UbiVac CMV, Inc. is developing effective therapeutic vaccines focused on the treatment of cancer. A major hurdle for the development of effect cancer vaccines is the inability of currently available cancer vaccines to induce a robust immune response against a broad spectrum of tumor antigens. UbiVac CMV's primary technology is a recombinant and replication-deficient Cytomegalovirus vaccine vector that it believes will allow the delivery of numerous tumor antigens simultaneously in a vector with capacity to amplify T-cell responses, resulting in a broad spectrum tumor-destructive immune response.
Viti is developing Tuberculosis (TB) diagnostics for adults and also young children. TB remains the leading infectious disease in the world with more than 40% of the world's population infected with Mycobacterium Tuberculosis (MTb). The worldwide resurgence of multiple drug resistant MTb has underscored the importance of TB diagnostics, especially in the pediatric population where the current TB diagnostics used for adults do not work. Viti's core technologies include a series of novel TB antigens and T cell clones as well as unique expertise in T cell expansion that will contribute to the development of successful TB diagnostics.